Affinity Asset Advisors LLC Decreases Stake in Oruka Therapeutics, Inc. $ORKA

Affinity Asset Advisors LLC decreased its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 37.7% during the 1st quarter, HoldingsChannel reports. The fund owned 499,673 shares of the company’s stock after selling 302,669 shares during the quarter. Oruka Therapeutics comprises approximately 1.3% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 24th largest holding. Affinity Asset Advisors LLC’s holdings in Oruka Therapeutics were worth $24,509,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ORKA. Viking Global Investors LP acquired a new stake in Oruka Therapeutics during the 3rd quarter valued at approximately $51,280,000. Deep Track Capital LP boosted its stake in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after buying an additional 735,983 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Oruka Therapeutics by 38.1% during the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after buying an additional 676,865 shares during the last quarter. RTW Investments LP grew its position in shares of Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after buying an additional 112,499 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth approximately $51,840,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Trading Up 0.2%

Shares of NASDAQ ORKA opened at $92.16 on Friday. Oruka Therapeutics, Inc. has a 12-month low of $12.84 and a 12-month high of $97.78. The company has a market cap of $5.56 billion, a price-to-earnings ratio of -47.50 and a beta of -0.35. The stock’s 50 day simple moving average is $75.38 and its 200 day simple moving average is $55.48.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. As a group, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on ORKA. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday, July 13th. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a research report on Monday, April 27th. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 23rd. Finally, Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $134.30.

Insider Activity

In other Oruka Therapeutics news, Director Carl Dambkowski sold 105,000 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the completion of the transaction, the director directly owned 73,743 shares of the company’s stock, valued at $4,348,624.71. The trade was a 58.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. This trade represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 188,406 shares of company stock worth $12,019,683. 23.49% of the stock is owned by insiders.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.